Pharmacological Inhibition of Glycoprotein VI- and Integrin α2β1-Induced Thrombus Formation Modulated by the Collagen Type
暂无分享,去创建一个
S. Watson | M. Gawaz | J. Heemskerk | N. Poulter | R. Farndale | Y. Henskens | M. Jandrot-Perrus | Natalie J. Jooss
[1] A. Sickmann,et al. Roles of Focal Adhesion Kinase PTK2 and Integrin αIIbβ3 Signaling in Collagen- and GPVI-Dependent Thrombus Formation under Shear , 2022, International journal of molecular sciences.
[2] Natalie S. Poulter,et al. Anti‐GPVI nanobody blocks collagen‐ and atherosclerotic plaque–induced GPVI clustering, signaling, and thrombus formation , 2022, Journal of thrombosis and haemostasis : JTH.
[3] B. Nieswandt,et al. Temporal Roles of Platelet and Coagulation Pathways in Collagen- and Tissue Factor-Induced Thrombus Formation , 2021, International journal of molecular sciences.
[4] P. Kirchhof,et al. GPVI inhibition by glenzocimab synergistically inhibits atherosclerotic plaque-induced platelet activation when combined with conventional dual antiplatelet therapy , 2021, European Heart Journal.
[5] B. Shah,et al. Transitioning From Thrombopoietin Agonists to the Novel SYK Inhibitor Fostamatinib: A Multicenter, Real-World Case Series , 2021, Journal of the advanced practitioner in oncology.
[6] P. Libby,et al. Targeting inflammation in atherosclerosis — from experimental insights to the clinic , 2021, Nature Reviews Drug Discovery.
[7] H. Schunkert,et al. Efficacy and Safety of Revacept, a Novel Lesion-Directed Competitive Antagonist to Platelet Glycoprotein VI, in Patients Undergoing Elective Percutaneous Coronary Intervention for Stable Ischemic Heart Disease: The Randomized, Double-blind, Placebo-Controlled ISAR-PLASTER Phase 2 Trial. , 2021, JAMA cardiology.
[8] J. Heemskerk,et al. Long-term platelet priming after glycoprotein VI stimulation in comparison to Protease-Activating Receptor (PAR) stimulation , 2021, PloS one.
[9] Natalie S. Poulter,et al. Structural characterisation of a novel GPVI nanobody-complex reveals a biologically active domain-swapped GPVI dimer. , 2021, Blood.
[10] J. Desilles,et al. Glenzocimab does not impact glycoprotein VI-dependent inflammatory hemostasis , 2020, Haematologica.
[11] S. Watson,et al. Novel antiplatelet strategies targeting GPVI, CLEC-2 and tyrosine kinases , 2020, Platelets.
[12] S. Watson,et al. Nonredundant Roles of Platelet Glycoprotein VI and Integrin αIIbβ3 in Fibrin-Mediated Microthrombus Formation. , 2020, Arteriosclerosis, thrombosis, and vascular biology.
[13] H. Diener,et al. Revacept, an Inhibitor of Platelet Adhesion in Symptomatic Carotid Artery Stenosis: Design and Rationale of a Randomized Phase II Clinical Trial , 2020, TH Open.
[14] O. Borst,et al. Glycoprotein VI - Novel target in antiplatelet medication. , 2020, Pharmacology & therapeutics.
[15] S. Watson,et al. Flow studies on human GPVI-deficient blood under coagulating and noncoagulating conditions. , 2020, Blood advances.
[16] Y. Plétan,et al. Population Pharmacokinetic/Pharmacodynamic Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen‐Induced Platelet Aggregation , 2020, Journal of clinical pharmacology.
[17] N. Mackman,et al. Therapeutic strategies for thrombosis: new targets and approaches , 2020, Nature Reviews Drug Discovery.
[18] H. ten Cate,et al. Role of Platelet Glycoprotein VI and Tyrosine Kinase Syk in Thrombus Formation on Collagen-Like Surfaces , 2019, International journal of molecular sciences.
[19] C. Hermans,et al. Platelet glycoprotein VI genetic quantitative and qualitative defects , 2019, Platelets.
[20] Y. Plétan,et al. Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab: First-in-Human Healthy Volunteer Trial , 2019, Arteriosclerosis, thrombosis, and vascular biology.
[21] S. Watson,et al. Functional significance of the platelet immune receptors GPVI and CLEC-2. , 2019, The Journal of clinical investigation.
[22] W. Ouwehand,et al. High-throughput elucidation of thrombus formation reveals sources of platelet function variability , 2018, Haematologica.
[23] Jacqueline K. White,et al. A synthesis approach of mouse studies to identify genes and proteins in arterial thrombosis and bleeding. , 2018, Blood.
[24] J. Heemskerk,et al. Platelet biology and functions: new concepts and clinical perspectives , 2018, Nature Reviews Cardiology.
[25] C. Weber,et al. Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque-triggered thrombus formation in humans. , 2018, Blood.
[26] B. Ho-Tin-Noé,et al. Glycoprotein VI in securing vascular integrity in inflamed vessels , 2018, Research and practice in thrombosis and haemostasis.
[27] S. Watson,et al. Immobilized fibrinogen activates human platelets through glycoprotein VI , 2018, Haematologica.
[28] Martine,et al. Immobilized fibrinogen activates human platelets through glycoprotein , 2018 .
[29] D. Bihan,et al. Differential integrin activity mediated by platelet collagen receptor engagement under flow conditions , 2017, Thrombosis and Haemostasis.
[30] R. W. Farndale,et al. Clustering of glycoprotein VI (GPVI) dimers upon adhesion to collagen as a mechanism to regulate GPVI signaling in platelets , 2017, Journal of thrombosis and haemostasis : JTH.
[31] C. Weber,et al. Recombinant GPVI-Fc added to single or dual antiplatelet therapy in vitro prevents plaque-induced platelet thrombus formation , 2017, Thrombosis and Haemostasis.
[32] C. Weber,et al. Cross-Linking GPVI-Fc by Anti-Fc Antibodies Potentiates Its Inhibition of Atherosclerotic Plaque- and Collagen-Induced Platelet Activation , 2016, JACC. Basic to translational science.
[33] Christopher M. Williams,et al. Coordinated Membrane Ballooning and Procoagulant Spreading in Human Platelets , 2015, Circulation.
[34] J. Heemskerk,et al. Multi-parameter assessment of thrombus formation on microspotted arrays of thrombogenic surfaces , 2014 .
[35] Rachel Cavill,et al. Identification of platelet function defects by multi-parameter assessment of thrombus formation , 2014, Nature Communications.
[36] R. Andrews,et al. Targeting GPVI as a novel antithrombotic strategy , 2014, Journal of blood medicine.
[37] K. Hamulýak,et al. Key role of integrin αIIbβ3 signaling to Syk kinase in tissue factor-induced thrombin generation , 2012, Cellular and Molecular Life Sciences.
[38] B. Nieswandt,et al. Platelet adhesion and activation mechanisms in arterial thrombosis and ischaemic stroke , 2011, Journal of thrombosis and haemostasis : JTH.
[39] M. Gawaz,et al. Novel Antiplatelet Drug Revacept (Dimeric Glycoprotein VI-Fc) Specifically and Efficiently Inhibited Collagen-Induced Platelet Aggregation Without Affecting General Hemostasis in Humans , 2011, Circulation.
[40] A. Tolcher,et al. Phase I Study of E7820, an Oral Inhibitor of Integrin α-2 Expression with Antiangiogenic Properties, in Patients with Advanced Malignancies , 2011, Clinical Cancer Research.
[41] P. D. de Groot,et al. Synergism between platelet collagen receptors defined using receptor-specific collagen-mimetic peptide substrata in flowing blood. , 2010, Blood.
[42] J. Molkentin,et al. Functional Divergence of Platelet Protein Kinase C (PKC) Isoforms in Thrombus Formation on Collagen* , 2010, The Journal of Biological Chemistry.
[43] P. Siljander,et al. Collagen‐mimetic peptides mediate flow‐dependent thrombus formation by high‐ or low‐affinity binding of integrin α2β1 and glycoprotein VI , 2008, Journal of thrombosis and haemostasis : JTH.
[44] E. Kremmer,et al. Platelet GPVI binds to collagenous structures in the core region of human atheromatous plaque and is critical for atheroprogression in vivo , 2008, Basic Research in Cardiology.
[45] Toshihiko Hayashi,et al. Collagen-type specificity of glycoprotein VI as a determinant of platelet adhesion , 2008, Platelets.
[46] D. Hammer,et al. GPVI and α2β1 play independent critical roles during platelet adhesion and aggregate formation to collagen under flow , 2005 .
[47] W. Ouwehand,et al. The FASEB Journal • Research Communication Human atheromatous plaques stimulate thrombus formation by activating platelet glycoprotein VI , 2022 .
[48] S. Watson,et al. Adhesion of human and mouse platelets to collagen under shear: a unifying model , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[49] M. V. van Zandvoort,et al. Principal Role of Glycoprotein VI in &agr;2&bgr;1 and &agr;IIb&bgr;3 Activation During Collagen-Induced Thrombus Formation , 2004 .
[50] J. Sixma,et al. The role of collagen in thrombosis and hemostasis , 2004, Journal of thrombosis and haemostasis : JTH.
[51] U. Heinzmann,et al. Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[52] Richard W Farndale,et al. Identification of the primary collagen-binding surface on human glycoprotein VI by site-directed mutagenesis and by a blocking phage antibody. , 2004, Blood.
[53] S. Santoro,et al. The contributions of the α2β1 integrin to vascular thrombosis in vivo , 2003 .
[54] S. Watson,et al. Platelet-collagen interaction: is GPVI the central receptor? , 2003, Blood.
[55] B. Nieswandt,et al. Integrin α2-Deficient Mice Develop Normally, Are Fertile, but Display Partially Defective Platelet Interaction with Collagen* , 2002, The Journal of Biological Chemistry.
[56] B. Nieswandt,et al. Glycoprotein VI but not α2β1 integrin is essential for platelet interaction with collagen , 2001 .
[57] Brian Savage,et al. Specific Synergy of Multiple Substrate–Receptor Interactions in Platelet Thrombus Formation under Flow , 1998, Cell.
[58] R. Farndale,et al. The platelet reactivity of synthetic peptides based on the collagen III fragment alpha1(III)CB4. Evidence for an integrin alpha2beta1 recognition site involving residues 522-528 of the alpha1(III) collagen chain. , 1997, The Journal of biological chemistry.
[59] R. Farndale,et al. The Platelet Reactivity of Synthetic Peptides Based on the Collagen III Fragment a1(III)CB4 EVIDENCE FOR AN INTEGRIN a2b1 RECOGNITION SITE INVOLVING RESIDUES 522–528 OF THE a1(III) COLLAGEN CHAIN* , 1997 .
[60] J. Sixma,et al. Platelet adhesion to collagen type IV under flow conditions. , 1996, Blood.
[61] J. Sixma,et al. Human blood platelets showing no response to collagen fail to express surface glycoprotein Ia , 1985, Nature.